Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
estimated completion

Description

Summary

The purpose of this study is to (1) describe patient and clinician engagement in web-based symptom self-monitoring, (2) identify differences in symptom management between intervention and usual care groups, and (3) identify potential outcomes of real-time symptom tracking and management. With the assistance of the study coordinator, participants randomized to the intervention will create an account with Noona. Patients will be instructed to log symptoms as often as relevant using their own personal devices. Patients will also be prompted once per week for 24 weeks to log any recent symptoms. These participants will be sent a Symptom Questionnaire (SQ) via the Noona tool that summarizes their symptoms and distress one week prior to each oncology clinic visit. Symptoms designated as clinically severe either during regular symptom logging or via the SQ will trigger a prompt to contact the clinical team for immediate follow-up.

Details

New patients from three cancer care programs (thoracic oncology, gastrointestinal oncology, and palliative care) at two academic institutions (Stanford and UCSF) will be screened for demographic and disease stage data within the patient medical record. Eligible patients will be asked by their oncology team whether they would be interested in participating a study of symptom management in oncology care. Patients who express interest and ability to participate will be interviewed to determine eligibility.

Keywords

Quality of Life Patient and clinician engagement Digital Symptom Tracking Use of Noona web- based symptom tracking tool Noona web-based symptom tracking tool

Eligibility

You can join if…

Open to people ages 18 years and up

  1. Individuals (men and women) aged 18 years or older
  2. Biopsy proven (recurrent or metastatic) advanced lung or gastrointestinal cancer
  3. No limit on prior lines of therapy in the metastatic setting
  4. ECOG performance status of 0-2
  5. Estimated life expectancy of at least 6 months
  6. Access to smartphone, tablet or computer with capability to utilize symptom tracking application
  7. Willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures
  8. Willing and able to comply with all study procedures

You CAN'T join if...

  1. Concurrent disease or condition that interferes with participation or safety
  2. Non-english speaking, as the application is developed in the english language
  3. Non-castrate resistant prostate cancer
  4. Enrolled in other non-therapeutic or therapeutic clinical trials

Locations

  • UCSF Helen Diller Medical Center
    San Francisco California 94115 United States
  • Stanford Cancer Institute
    Palo Alto California 94305 United States

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
Stanford University
ID
NCT05112198
Study Type
Interventional
Last Updated